GRAL
GRAIL, Inc.
There isn't enough reported data to score GRAL yet.
HIMS
Hims & Hers Health, Inc.
There isn't enough reported data to score HIMS yet.
GRAL Fundamentals
| Metric | Status |
|---|---|
| Healthy | |
| Under pressure | |
| Weak | |
| Unavailable |
GRAL's revenue is currently healthy, but its profitability and cash flow are under pressure. There isn't enough data to rate its balance sheet.
HIMS Fundamentals
| Metric | Status |
|---|---|
| Strong | |
| Weak | |
| Stable | |
| Strong |
HIMS's revenue and balance sheet are currently strong, and its cash flow is stable, but its profitability is weak.
GRAL PE Valuation
GRAL has no meaningful PE right now: it lost money over the past year.
HIMS PE Valuation
HIMS has no meaningful PE right now: it lost money over the past year.
GRAL Forward outlook
| Metric | Outlook |
|---|---|
| -- | |
| Losses steady | |
| Growth | |
| -- | |
| Limited | |
| Moderate |
Analysts expect GRAL's revenue to grow, with its earnings and profitability holding steady.
HIMS Forward outlook
| Metric | Outlook |
|---|---|
| -- | |
| Turning to a loss | |
| Strong growth | |
| Stable | |
| Limited | |
| Low |
Analysts expect HIMS's revenue to grow, but its earnings to decline. However, they disagree widely on these estimates.
GRAL Earnings Per Share
| Quarter | TTM EPS | YoY |
|---|---|---|
| Q3 2026 | -$9.43 | +$2.35 |
| Q2 2026 | -$9.68 | +$3.58 |
| Q1 2026 | -$10.30 | +$50.84 |
| Q4 2025 | -$11.11 | +$53.98 |
| Q3 2025 | -$11.78 | +$50.45 |
| Q2 2025 | -$13.26 | +$73.74 |
| Q1 2025 | -$61.14 | -$18.98 |
| Q4 2024 | -$65.09 | -$23.74 |
GRAL has the edge over HIMS on earnings, with more consistent year-over-year improvement.
HIMS Earnings Per Share
| Quarter | TTM EPS | YoY |
|---|---|---|
| Q3 2026 | -$0.83 | -257% |
| Q2 2026 | -$0.63 | -180% |
| Q1 2026 | -$0.09 | -113% |
| Q4 2025 | $0.51 | -3.8% |
| Q3 2025 | $0.53 | +20% |
| Q2 2025 | $0.79 | +888% |
| Q1 2025 | $0.68 | +$0.69 |
| Q4 2024 | $0.53 | +$0.64 |
HIMS has swung to a loss: it lost $0.83 per share over the past year, after a profit the year before.
GRAL Quarterly Revenue
| Quarter | Revenue | YoY |
|---|---|---|
| Q3 2026 | $37.5M | +3.7% |
| Q2 2026 | $44.7M | +26% |
| Q1 2026 | $40.8M | +28% |
| Q4 2025 | $43.6M | +14% |
| Q3 2025 | $36.2M | +26% |
| Q2 2025 | $35.5M | +11% |
| Q1 2025 | $31.8M | +19% |
| Q4 2024 | $38.3M | +26% |
GRAL's revenue has grown year over year every quarter since early 2024: $38M last quarter, up 3.7% from the same quarter a year ago.
| Quarter | Margin | YoY |
|---|---|---|
| Q3 2026 | -385% | -39 points |
| Q2 2026 | -389% | +58 points |
| Q1 2026 | -333% | +150 points |
| Q4 2025 | -285% | +73 points |
| Q3 2025 | -346% | +294 points |
| Q2 2025 | -447% | +4687 points |
| Q1 2025 | -482% | +369 points |
| Q4 2024 | -358% | +284 points |
GRAL's operating margin was −385% last quarter, down 39 points from the same quarter a year ago.
HIMS Quarterly Revenue
| Quarter | Revenue | YoY |
|---|---|---|
| Q3 2026 | $890.4M | +49% |
| Q2 2026 | $753.2M | +38% |
| Q1 2026 | $608.1M | +3.8% |
| Q4 2025 | $617.8M | +28% |
| Q3 2025 | $599M | +49% |
| Q2 2025 | $544.8M | +73% |
| Q1 2025 | $586M | +111% |
| Q4 2024 | $481.1M | +95% |
HIMS has the edge over GRAL on sales, with stronger typical year-over-year growth.
| Quarter | Margin | YoY |
|---|---|---|
| Q3 2026 | -7.4% | -9.4 points |
| Q2 2026 | -13% | -18 points |
| Q1 2026 | -13% | -23 points |
| Q4 2025 | 1.5% | -2.4 points |
| Q3 2025 | 2% | -3.6 points |
| Q2 2025 | 4.9% | +1.4 points |
| Q1 2025 | 9.9% | +6.3 points |
| Q4 2024 | 3.9% | +4 points |
HIMS has the edge over GRAL on profitability, with a higher operating margin.
GRAL Free Cash Flow
| Quarter | Free cash flow | YoY |
|---|---|---|
| Q3 2026 | -$79.5M | -$15.8M |
| Q2 2026 | -$81.2M | -$3.8M |
| Q1 2026 | -$87.5M | +$7.6M |
| Q3 2025 | -$63.6M | +$41M |
| Q1 2025 | -$95.1M | +$114.8M |
| Q3 2024 | -$104.6M | +$56M |
| Q1 2024 | -$209.8M | -$36.3M |
GRAL has burned cash in almost every quarter: −$312M over the past year, against −$341M the year before.
HIMS Free Cash Flow
| Quarter | Free cash flow | YoY |
|---|---|---|
| Q3 2026 | $26M | -67% |
| Q2 2026 | -$68.2M | +$1.3M |
| Q1 2026 | $53.1M | +5.9% |
| Q3 2025 | $79.3M | -7% |
| Q2 2025 | -$69.5M | -230% |
| Q1 2025 | $50.1M | +94% |
| Q3 2024 | $85.3M | +238% |
| Q2 2024 | $53.6M | +219% |
HIMS has the edge over GRAL on cash generation, producing positive trailing cash flow while its opponent burns cash.
GRAL Total Shares
| Period | Change % | Net change |
|---|---|---|
| Quarterly | +8.5% | +3.7M shares |
| 1 year | +29% | +10.7M shares |
| 3 years | +51% | +15.7M shares |
GRAL has 47M diluted shares, up 29% from a year ago.
| Quarter | Spent |
|---|---|
| Q1 2024 | — |
| Q4 2023 | $14,000 |
| Q3 2023 | — |
| Q2 2023 | $95,000 |
| Q1 2023 | — |
HIMS Total Shares
| Period | Change % | Net change |
|---|---|---|
| Quarterly | +0.9% | +2.1M shares |
| 1 year | -6% | -14.9M shares |
| 3 years | +11% | +23.7M shares |
| 5 years | +17% | +33.8M shares |
HIMS has the edge over GRAL on shareholder dilution, with a more favorable share count trend.
| Quarter | Spent |
|---|---|
| Q4 2025 | $80.5M |
| Q3 2025 | $9.5M |
| Q2 2025 | — |
| Q1 2025 | — |
| Q4 2024 | $5M |
| Q3 2024 | $30M |
| Q2 2024 | $19.9M |
| Q1 2024 | $28.1M |
GRAL Net Leverage
GRAL's operating earnings (EBITDA) were negative over the past year, so its debt can't be measured against them.
HIMS Net Leverage
| Quarter | Net Leverage | Status |
|---|---|---|
| Q1 2026 | -5.9x | Net Cash |
| Q4 2025 | -1.4x | Net Cash |
| Q3 2025 | -2.2x | Net Cash |
| Q2 2025 | -7.3x | Net Cash |
| Q1 2025 | -2.1x | Net Cash |
| Q4 2024 | -2.8x | Net Cash |
| Q3 2024 | -2.9x | Net Cash |
| Q2 2024 | -5.5x | Net Cash |
HIMS has more cash than debt.
GRAL Weekly Momentum
| Metric | Value | Status |
|---|---|---|
| RSI | 60.0 | Neutral |
| Stochastic | 63.5 | Neutral |
GRAL's weekly RSI is 60 (neutral) and its Stochastic is 64 (neutral).
HIMS Weekly Momentum
| Metric | Value | Status |
|---|---|---|
| RSI | 36.0 | Neutral |
| Stochastic | 23.0 | Neutral |
HIMS's weekly RSI is 36 (neutral) and its Stochastic is 23 (neutral).
GRAL PE vs Healthcare Sector
GRAL has no meaningful PE right now: it lost money over the past year.
HIMS PE vs Healthcare Sector
| Metric | HIMS | Sector median | Relative |
|---|---|---|---|
| PE | N/A | 26x | — |
HIMS has no meaningful PE right now: it lost money over the past year.
GRAL Weekly Moving Averages
| Moving average | MA price | Relative |
|---|---|---|
| 8 week MA | $130.9 | 7.3% below |
| 20 week MA | $96.6 | 26% above |
| 50 week MA | $81.1 | 50% above |
| 100 week MA | $62.1 | 95% above |
GRAL has stronger trend alignment. GRAL is above 3 of 4 weekly averages versus HIMS above 0 of 5.
HIMS Weekly Moving Averages
| Moving average | MA price | Relative |
|---|---|---|
| 8 week MA | $27.3 | 28% below |
| 20 week MA | $29.2 | 32% below |
| 50 week MA | $27.7 | 29% below |
| 100 week MA | $35.9 | 45% below |
| 200 week MA | $24.4 | 19% below |
HIMS is in a downtrend: it's below all five of its weekly moving averages, and 19% below its 200-week average.
GRAL Yearly ROI
| Year | Start price | End price | ROI |
|---|---|---|---|
| 2024 | $17.2 | $19.6 | +14% |
| 2025 | $19.6 | $91.6 | +367% |
| 2026 YTD | $91.6 | $121.4 | +32% |
GRAL has the edge over HIMS on returns for 2026, with the stronger performance.
HIMS Yearly ROI
| Year | Start price | End price | ROI |
|---|---|---|---|
| 2020 | $9.89 | $15.0 | +51% |
| 2021 | $15.0 | $6.65 | -56% |
| 2022 | $6.65 | $6.43 | -3.3% |
| 2023 | $6.43 | $8.90 | +38% |
| 2024 | $8.90 | $26.6 | +198% |
| 2025 | $26.6 | $34.3 | +29% |
| 2026 YTD | $34.3 | $19.7 | -42% |
HIMS's yearly returns have swung widely, from +198% in 2024 to −56% in 2021. It's down 42% so far in 2026.